BRAF and neoplasm: Appraising the PFS and RR scenarios, it was conceivable that BRAFi‐MEKi would dominate them, as BRAF‐MEK inhibition was already known to produce frequent and rapid responses, whereas immunotherapy may take longer to produce sustained tumor shrinkage and even lead to unconventional response patterns not properly captured by the standard response assessments 18, 37, 38.